Skip to search formSkip to main contentSkip to account menu

CXA-101

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ceftolozane

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Looking for the new preparations for antibacterial therapy. II. Clinical trials; new beta-lactam antibiotics and beta-lactamase inhibitors.
To obtain a status of a medicinal product, a compound possessing potential antimicrobial activity and displaying no cytotoxicity… 
Highly Cited
2011
Highly Cited
2011
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
2009
2009
In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance
ABSTRACT We describe the activity of a novel cephalosporin, CXA-101 (FR26 4205), against a panel of highly resistant Pseudomonas… 
2009
2009
Activity of the Novel Cephalosporin CXA-101 Tested in Combination with Tazobactam against Cephalosporin-resistant Enterobacteriaceae, P. aeruginosa and B. fragilis
Results: Highest enhanced effect of CXA activity was noted with CXA/TAZ4 and CXA/TAZ2:1. CXA/TAZ4 was ≥16-fold and 2- to 8-fold… 
2009
2009
In Vitro Activity of CXA-101, a Novel Cephalosporin, Against Resistant Phenotypes of Pseudomonas aeruginosa (PSA)
2008
2008
Mode of Action of CXA-101 Based on Minimum Bactericidal Concentration (MBC) Analysis and Timekill Kinetic (TK) Analysis
2008
2008
Activity Profile of CXA-101 against Gram-Positive and Gram-Negative Pathogens by Broth and Agar Dilution
2008
2008
Effect of Various Testing Parameters on the Activity of CXA-101 by Broth Microdilution
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)